Zenocutuzumab - Merus
Alternative Names: HER3 x HER2 Biclonics®; MCLA-128; Zeno; Zenocutuzomab - MerusLatest Information Update: 15 May 2024
At a glance
- Originator Merus
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists; ERBB-3 receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preregistration Non-small cell lung cancer; Pancreatic cancer
- Phase II Breast cancer; Prostate cancer
- Phase I/II Solid tumours